BNP Paribas Financial Markets Purchases 225,222 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

BNP Paribas Financial Markets boosted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 66.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 565,976 shares of the biopharmaceutical company’s stock after acquiring an additional 225,222 shares during the period. BNP Paribas Financial Markets owned 0.19% of Amicus Therapeutics worth $6,045,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. OLD Second National Bank of Aurora bought a new stake in shares of Amicus Therapeutics during the third quarter worth about $26,000. Hazlett Burt & Watson Inc. raised its stake in shares of Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 1,569 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI purchased a new position in shares of Amicus Therapeutics during the third quarter valued at approximately $32,000. Finally, Headlands Technologies LLC purchased a new position in shares of Amicus Therapeutics during the second quarter valued at approximately $89,000.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on FOLD shares. StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday. Guggenheim boosted their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. Jefferies Financial Group began coverage on Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 target price on the stock. Finally, JPMorgan Chase & Co. increased their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $17.63.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,884,273.08. This represents a 0.84 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 30,401 shares of company stock valued at $339,363 over the last ninety days. 2.20% of the stock is currently owned by insiders.

Amicus Therapeutics Trading Down 1.7 %

NASDAQ:FOLD opened at $9.79 on Wednesday. Amicus Therapeutics, Inc. has a 12 month low of $9.02 and a 12 month high of $14.57. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The firm’s 50 day moving average is $10.68 and its 200 day moving average is $10.61.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.